Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

por Escobar, Carlos, Morales, Cristóbal, Capel, Margarita, Simón, Susana, Pérez-Alcántara, Ferran, Pomares, Elisenda
Publicado 2022